Arrowhead Research Corporation is a clinical stage nanomedicine company developing innovative therapies at the interface of biology and nanoengineering. The Company has clinical programs in small RNA therapeutics and obesity. Arrowhead's programs are based on its proprietary drug development and delivery platforms, each capable of creating multiple therapeutic products. This strategy seeks to enhance the return potential for investors and reduce risk compared to traditional biotech companies. Arrowhead's world-class capabilities and intellectual property covering nucleic acid delivery, siRNA chemistry, and tissue targeting allow it to optimize therapeutic agents for a wide range of diseases.

The company's lead products include:

• CALAA-01, an oncology drug candidate based on the gene silencing RNA interference (RNAi) mechanism
• Adipotide, an anti-obesity peptide that targets and kills the blood vessels that feed white adipose tissue
• RNAi development programs for hepatitis B virus and targeting
  HIF-2a for solid tumors

Arrowhead is leveraging its proprietary Dynamic Polyconjugate (DPC), Liposomal Nanoparticle (LNP), and RONDEL delivery platforms to support its own pipeline of preclinical and clinical candidates, and to secure external partnerships and collaborations with biotech and pharmaceutical companies. Arrowhead believes this comprehensive suite of delivery solutions, with its broad license to the three primary siRNA structures, positions the company as the partner of choice for small RNA therapeutics.